Relapse · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab probably leads to lower number of participants experiencing ≥ 1 relapse compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Number of participants with any serious adverse events · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of adverse events requiring discontinuation of treatment ‐ not reported · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants experiencing treatment discontinuation caused… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants with new or enlarging T2‐hyperintense lesions on MRI · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants experiencing disability progression · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing disability progression compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with any adverse events · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any adverse events compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Number of participants with any serious adverse events · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants with gadolinium‐enhancing T1 lesions on MRI compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with new or enlarging T2‐hyperintense lesions on MRI · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants with new or enlarging T2‐hyperintense lesions… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants experiencing disability progression · primary progressive multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing disability progression compared with placebo (low certainty).
1 finding from 1 review
Number of participants with any adverse events · primary progressive multiple sclerosis
Ocrelizumab probably leads to higher number of participants with any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Ocrelizumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes ocrelizumab No direct evidence (very low certainty).
1 finding from 1 review
RR 0.61 [0.41, 0.9]
Studies not reported
Very low
Intervention not reported
Ocrelizumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in ocrelizumab No direct evidence (low certainty).
1 finding from 1 review
OR 0.82 [0.42, 1.6]
Studies not reported
Low
Intervention not reported
Ocrelizumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes ocrelizumab No direct evidence (very low certainty).
1 finding from 1 review
OR 1 [0.58, 1.72]
Studies not reported
Very low
Ocrelizumab · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes ocrelizumab compared with other disease‐modifying treatments (very low certainty).
1 finding from 1 review
OR 0.02 [0, 0.4]
472 participants
Very low
Intervention not reported
Intervention (no. of studies and participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Alemtuzumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower alemtuzumab No direct evidence (low certainty).
1 finding from 1 review
RR 0.67 [0.46, 0.99]
Studies not reported
Low
Intervention not reported
Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).
1 finding from 1 review